Key result
GALACTIC-HF-eligible patients on GDMT show a ~16% mortality reduction for EF ≤28% despite similar hospitalizations.
Why the study?
Randomized clinical trials in populations with HFrEF may not reflect the general HFrEF population, leaving the representativeness of GALACTIC-HF unclear.
Are patients enrolled in the GALACTIC-HF trial representative of a real-world HFrEF population, and how do their outcomes compare?
Population
9770 patients with HFrEF from 2014 to 2018 in Kaiser Permanente Southern California
Comparison
GALACTIC-HF-eligible cohorts (EF ≤28%, EF 29%-35%) vs ineligible cohorts (taking or not taking GDMT)
Design
Retrospective electronic health record cohort study
Follow-up
1 year
Authors
Loading...
High event rates persist among real-world GALACTIC-HF-eligible HFrEF patients on GDMT; leaves open trial generalizability to ineligible cohorts.
Cohort (n=9,770)
Are patients enrolled in the GALACTIC-HF trial representative of a real-world HFrEF population, and how do their outcomes compare?
Effect estimate: HR 0.84 (95% CI 0.72-0.98)
A large proportion of real-world HFrEF patients met GALACTIC-HF inclusion criteria and demonstrated high hospitalization rates despite GDMT, highlighting the need for novel therapies.
Mefford et al. (2022) conducted a cohort in Heart failure with reduced ejection fraction (n=9,770). GALACTIC-HF-eligible cohort with EF ≤28% vs. GALACTIC-HF-ineligible cohort not taking GDMT was evaluated on 1-year mortality (HR 0.84, 95% CI 0.72-0.98). GALACTIC-HF-eligible patients on GDMT had similar hospitalization rates to ineligible patients not taking GDMT, though 1-year mortality was lower (HR 0.84; 95% CI 0.72-0.98 for EF ≤28%).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: